Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation

Fallowfield, L J, Kilburn, L S, Langridge, C, Snowdon, C F, Bliss, J M and Coombes, R C (2012) Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation. British Journal of Cancer, 106 (6). pp. 1062-1067. ISSN 0007-0920

Full text not available from this repository.


Background:The Intergroup Exemestane Study (IES) (ISRCTN11883920) demonstrated improved survival for postmenopausal women with ER-positive/unknown primary breast cancer who switched to exemestane after 2-3 years tamoxifen, compared with those continuing on tamoxifen to complete 5 years therapy. This was achieved without detriment to on-treatment quality-of-life (QoL). We report on- and post-treatment QoL impact in IES.Methods:A total of 582 patients from 8 countries participated in the QoL substudy. Functional Assessment of Cancer Therapy-Breast (FACT-B) and endocrine symptom subscale (ES) were completed at baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 months. The primary endpoint was FACT-B Trial Outcome Index (TOI); secondary endpoints included severity of individual endocrine symptoms.Results:Both the groups showed gradual improvement in overall QoL and lessening of total endocrine symptoms post treatment compared with baseline (P<0.002). There was no evidence of any between-group differences in TOI. Vasomotor complaints remained high on treatment. Vaginal discharge was more frequent (P<0.01) with tamoxifen up to 24 months from baseline. In both the groups, post-treatment libido did not recover to baseline levels.Conclusion:Clinical benefits of switching to exemestane are accompanied by good overall QoL. Although some symptoms persist, the majority of endocrine symptoms improve after treatment completion.

Item Type: Article
Additional Information: Fallowfield, L J Kilburn, L S Langridge, C Snowdon, C F Bliss, J M Coombes, R C On behalf of the IES Trial Steering Committee England British journal of cancer Br J Cancer. 2012 Mar 13;106(6):1062-7. doi: 10.1038/bjc.2012.43. Epub 2012 Feb 21.
Keywords: aromatase inhibitor, breast cancer, exemestane, oestrogen receptor, quality of life
Schools and Departments: Brighton and Sussex Medical School > Sussex Health Outcomes Research & Education in Cancer (SHORE-C)
Subjects: R Medicine
R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology Including cancer and carcinogens
R Medicine > RG Gynecology and obstetrics > RG0491 Diseases of the breast
R Medicine > RM Therapeutics. Pharmacology > RM0260 Chemotherapy
Related URLs:
Depositing User: Kathryn Monson
Date Deposited: 17 Apr 2012 11:56
Last Modified: 30 Nov 2012 17:12
URI: http://srodev.sussex.ac.uk/id/eprint/38592
📧 Request an update